Bi­par­ti­san group of sen­a­tors seeks to elim­i­nate in­ter­change­abil­i­ty des­ig­na­tion for biosim­i­lars

The US biosim­i­lar mar­ket has al­ways been dis­tinct from the EU mar­ket, par­tic­u­lar­ly when it comes to the des­ig­na­tion of cer­tain biosim­i­lars as be­ing in­ter­change­able or al­lowed to be switched at the phar­ma­cy counter for their brand name coun­ter­parts with­out a physi­cian’s in­ter­ven­tion.

On­ly a small hand­ful of com­pa­nies have won this des­ig­na­tion so far in the US, where­as all biosim­i­lars are deemed in­ter­change­able in the EU. Now, a group of bi­par­ti­san sen­a­tors is look­ing to align the US and EU fur­ther, and elim­i­nate the in­ter­change­abil­i­ty des­ig­na­tion in the US.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER